| Year |
Citation |
Score |
| 2024 |
Saha A, Palchaudhuri R, Lanieri L, Hyzy S, Riddle MJ, Panthera J, Eide C, Tolar J, Panoskaltsis-Mortari A, Gorfinkel L, Tkachev V, Gerdemann U, Alvarez-Calderon F, Palato ER, MacMillan ML, ... ... Osborn M, et al. Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate conditioned Fanconi anemia mice. Blood. PMID 38447038 DOI: 10.1182/blood.2023023549 |
0.439 |
|
| 2023 |
Feser CJ, Williams JM, Lammers DT, Bingham JR, Eckert MJ, Tolar J, Osborn MJ. Engineering Human Cells Expressing CRISPR/Cas9-Synergistic Activation Mediators for Recombinant Protein Production. International Journal of Molecular Sciences. 24. PMID 37239814 DOI: 10.3390/ijms24108468 |
0.327 |
|
| 2023 |
Larson JH, Jin S, Loschi M, Wagers SB, Thangavelu G, Zaiken MC, McDonald-Hyman C, Saha A, Aguilar EG, Koehn B, Osborn MJ, Panoskaltsis-Mortari A, Macdonald KPA, Hill GR, Murphy WJ, et al. Enforced gut homing of murine regulatory T cells reduces early graft-versus-host disease severity. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 36878433 DOI: 10.1016/j.ajt.2023.01.030 |
0.483 |
|
| 2022 |
Pennell CA, Campbell H, Storlie MD, Bolivar-Wagers S, Osborn MJ, Refaeli Y, Jensen M, Viaud S, Young TS, Blazar BR. Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19 malignancy. Journal For Immunotherapy of Cancer. 10. PMID 36521930 DOI: 10.1136/jitc-2022-005934 |
0.503 |
|
| 2022 |
Neugebauer ME, Hsu A, Arbab M, Krasnow NA, McElroy AN, Pandey S, Doman JL, Huang TP, Raguram A, Banskota S, Newby GA, Tolar J, Osborn MJ, Liu DR. Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity. Nature Biotechnology. PMID 36357719 DOI: 10.1038/s41587-022-01533-6 |
0.301 |
|
| 2022 |
Sipe CJ, Kluesner MG, Bingea SP, Lahr WS, Andrew AA, Wang M, DeFeo AP, Hinkel TL, Laoharawee K, Wagner JE, MacMillan ML, Vercellotti GM, Tolar J, Osborn MJ, McIvor RS, et al. Correction of Fanconi Anemia Mutations Using Digital Genome Engineering. International Journal of Molecular Sciences. 23. PMID 35955545 DOI: 10.3390/ijms23158416 |
0.741 |
|
| 2022 |
Bolivar-Wagers S, Loschi ML, Jin S, Thangavelu G, Larson JH, McDonald-Hyman CS, Aguilar EA, Saha A, Koehn BH, Hefazi M, Osborn MJ, Jensen MC, Wagner JE, Pennell CA, Blazar BR. Murine CAR19 Tregs suppress acute graft-versus-host disease and maintain graft-versus-tumor responses. Jci Insight. PMID 35917188 DOI: 10.1172/jci.insight.160674 |
0.489 |
|
| 2022 |
Meyer-Mueller C, Osborn MJ, Tolar J, Boull C, Ebens CL. Revertant Mosaicism in Epidermolysis Bullosa. Biomedicines. 10. PMID 35052793 DOI: 10.3390/biomedicines10010114 |
0.32 |
|
| 2021 |
Knipping F, Newby GA, Eide CR, McElroy AN, Nielsen SC, Smith K, Fang Y, Cornu TI, Costa C, Gutierrez-Guerrero A, Bingea SP, Feser CJ, Steinbeck B, Hippen KL, Blazar BR, ... ... Osborn MJ, et al. Disruption of HIV-1 co-receptors CCR5 and CXCR4in primary human T cells and hematopoietic stemand progenitor cells using base editing. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 34737067 DOI: 10.1016/j.ymthe.2021.10.026 |
0.484 |
|
| 2021 |
Hippen KL, Furlan SN, Roychoudhuri R, Wang E, Zhang Y, Osborn MJ, Merkel SC, Hani S, MacMillan ML, Cichocki F, Miller JS, Wagner JE, Restifo NP, Kean LS, Blazar BR. Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion. Cytotherapy. PMID 33893050 DOI: 10.1016/j.jcyt.2021.02.118 |
0.499 |
|
| 2021 |
Osborn MJ, Bhardwaj A, Bingea SP, Knipping F, Feser CJ, Lees CJ, Collins DP, Steer CJ, Blazar BR, Tolar J. CRISPR/Cas9-Based Lateral Flow and Fluorescence Diagnostics. Bioengineering (Basel, Switzerland). 8. PMID 33673107 DOI: 10.3390/bioengineering8020023 |
0.334 |
|
| 2020 |
Thangavelu G, Wang C, Loschi M, Saha A, Osborn M, Furlan SN, Aoyama K, McDonald-Hyman C, Aguilar EG, Janesick AS, Chandraratna RA, Refaeli Y, Panoskaltsis-Mortari A, MacDonald KP, Hill GR, et al. Repurposing a novel anti-cancer RXR agonist to attenuate acute GVHD and maintain graft-versus-leukemia responses. Blood. PMID 32976550 DOI: 10.1182/blood.2020005628 |
0.495 |
|
| 2019 |
Webber BR, Lonetree CL, Kluesner MG, Johnson MJ, Pomeroy EJ, Diers MD, Lahr WS, Draper GM, Slipek NJ, Smeester BA, Lovendahl KN, McElroy AN, Gordon WR, Osborn MJ, Moriarity BS. Author Correction: Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nature Communications. 10: 5659. PMID 31811147 DOI: 10.1038/S41467-019-13778-Y |
0.689 |
|
| 2019 |
Webber BR, Lonetree CL, Kluesner MG, Johnson MJ, Pomeroy EJ, Diers MD, Lahr WS, Draper GM, Slipek NJ, Smeester BS, Lovendahl KN, McElroy AN, Gordon WR, Osborn MJ, Moriarity BS. Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nature Communications. 10: 5222. PMID 31745080 DOI: 10.1038/S41467-019-13007-6 |
0.737 |
|
| 2019 |
Saha A, Taylor PA, Lees CJ, Panoskaltsis-Mortari A, Osborn MJ, Feser CJ, Thangavelu G, Melchinger W, Refaeli Y, Hill GR, Munn DH, Murphy WJ, Serody JS, Maillard I, Kreymborg K, et al. Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. Jci Insight. 4. PMID 31578305 DOI: 10.1172/Jci.Insight.127716 |
0.519 |
|
| 2019 |
Osborn MJ, Newby GA, McElroy AN, Knipping F, Nielsen SC, Riddle MJ, Xia L, Chen W, Eide CR, Webber BR, Wandall HH, Dabelsteen S, Blazar BR, Liu DR, Tolar J. Base editor correction of COL7A1 in recessive dystrophic epidermolysis bullosa patient-derived fibroblasts and iPSCs. The Journal of Investigative Dermatology. PMID 31437443 DOI: 10.1016/J.Jid.2019.07.701 |
0.753 |
|
| 2019 |
Lonetree C, Webber BR, Diers MD, Lahr WS, Kluesner M, Osborn MJ, Johnson MJ, Moriarity BS. Abstract A036: Multiplex human T-cell engineering by Cas9 base editor technology Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A036 |
0.483 |
|
| 2019 |
Osborn M, Newby G, Knipping F, Liu D, Tolar J. 374 CRISPR/Cas9-base editing mediated correction for recessive dystrophic epidermolysis bullosa Journal of Investigative Dermatology. 139: S65. DOI: 10.1016/J.Jid.2019.03.450 |
0.335 |
|
| 2018 |
McDonald-Hyman C, Muller JT, Loschi M, Thangavelu G, Saha A, Kumari S, Reichenbach DK, Smith MJ, Zhang G, Koehn BH, Lin J, Mitchell JS, Fife BT, Panoskaltsis-Mortari A, Feser CJ, ... ... Osborn MJ, et al. The vimentin intermediate filament network restrains regulatory T-cell suppression of graft-versus-host disease. The Journal of Clinical Investigation. PMID 30106752 DOI: 10.1172/Jci95713 |
0.535 |
|
| 2018 |
Pennell CA, Barnum JL, McDonald-Hyman CS, Panoskaltsis-Mortari A, Riddle MJ, Xiong Z, Loschi M, Thangavelu G, Campbell HM, Storlie MD, Refaeli Y, Furlan SN, Jensen MC, Kean LS, Miller JS, ... ... Osborn MJ, et al. Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29735365 DOI: 10.1016/J.Ymthe.2018.04.006 |
0.556 |
|
| 2018 |
Vanden Oever M, Twaroski K, Osborn MJ, Wagner JE, Tolar J. Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa. Pediatric Research. 83: 318-324. PMID 29593249 DOI: 10.1038/Pr.2017.244 |
0.429 |
|
| 2018 |
Osborn MJ, Lees CJ, McElroy AN, Merkel SC, Eide CR, Mathews W, Feser CJ, Tschann M, McElmury RT, Webber BR, Kim CJ, Blazar BR, Tolar J. CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression. International Journal of Molecular Sciences. 19. PMID 29565806 DOI: 10.3390/Ijms19040946 |
0.756 |
|
| 2018 |
Yoon DH, Osborn MJ, Tolar J, Kim CJ. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T. International Journal of Molecular Sciences. 19. PMID 29364163 DOI: 10.3390/Ijms19020340 |
0.399 |
|
| 2017 |
Webber BR, O'Connor KT, McElmurry RT, Durgin EN, Eide CR, Lees CJ, Riddle MJ, Mathews WE, Frank NY, Kluth MA, Ganss C, Moriarity BS, Frank MH, Osborn MJ, Tolar J. Rapid generation of Col7a1(-/-) mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 28892093 DOI: 10.1038/Labinvest.2017.85 |
0.732 |
|
| 2017 |
Skvarova Kramarzova K, Osborn MJ, Webber BR, DeFeo AP, McElroy AN, Kim CJ, Tolar J. CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells. International Journal of Molecular Sciences. 18. PMID 28613254 DOI: 10.3390/Ijms18061269 |
0.748 |
|
| 2017 |
Knipping F, Osborn MJ, Petri K, Tolar J, Glimm H, von Kalle C, Schmidt M, Gabriel R. Genome-wide Specificity of Highly Efficient TALENs and CRISPR/Cas9 for T Cell Receptor Modification. Molecular Therapy. Methods & Clinical Development. 4: 213-224. PMID 28345006 DOI: 10.1016/J.Omtm.2017.01.005 |
0.471 |
|
| 2017 |
Tolar J, McGrath J, Osborn M, Keene D, Riddle M, Hook K, Hordinsky M, Marinkovich M, Woodley D, Chen M, Tryon R, DeFor T, Ebens C, Tamai K, Hovnanian A, et al. 377 Type VII collagen (C7) expression and chimerism after bone marrow/cord blood transplantation (BMCBT) for severe generalized recessive dystrophic epidermolysis bullosa (RDEB) Journal of Investigative Dermatology. 137. DOI: 10.1016/J.Jid.2017.02.394 |
0.322 |
|
| 2017 |
Hook K, Tolar J, McGrath J, Osborn M, Keene D, Riddle M, Hordinsky M, Marinkovich M, Tryon R, DeFor T, Ebens C, Tamai K, Hovnanian A, Blazar B, Wagner J. 308 Bone marrow/cord blood transplantation (BMCBT) ameliorates symptoms in some, but not all, subtypes of severe generalized junctional epidermolysis bullosa (JEB) Journal of Investigative Dermatology. 137. DOI: 10.1016/J.Jid.2017.02.324 |
0.422 |
|
| 2016 |
Webber BR, Osborn MJ, McElroy AN, Twaroski K, Lonetree CL, DeFeo AP, Xia L, Eide C, Lees CJ, McElmurry RT, Riddle MJ, Kim CJ, Patel DD, Blazar BR, Tolar J. CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. Npj Regenerative Medicine. 1. PMID 28250968 DOI: 10.1038/Npjregenmed.2016.14 |
0.769 |
|
| 2016 |
Osborn MJ, Webber BR, McElmurry RT, Rudser KD, DeFeo AP, Muradian M, Petryk A, Hallgrimsson B, Blazar BR, Tolar J, Braunlin EA. Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology. Journal of Inherited Metabolic Disease. PMID 27743312 DOI: 10.1007/S10545-016-9988-Z |
0.679 |
|
| 2016 |
Osborn M, Lonetree CL, Webber BR, Patel D, Dunmire S, McElroy AN, DeFeo AP, MacMillan ML, Wagner J, Balzar BR, Tolar J. CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia. Stem Cells and Development. PMID 27538887 DOI: 10.1089/scd.2016.0149 |
0.727 |
|
| 2016 |
Osborn MJ, Belanto JJ, Tolar J, Voytas DF. Gene editing and its application for hematological diseases. International Journal of Hematology. 104: 18-28. PMID 27233509 DOI: 10.1007/S12185-016-2017-Z |
0.465 |
|
| 2016 |
Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, McElroy AN, Starker CG, Lee C, Merkel S, Lund TC, Kelly-Spratt KS, Jensen MC, Voytas DF, von Kalle C, et al. Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Molecular Therapy : the Journal of the American Society of Gene Therapy. 24: 570-81. PMID 26502778 DOI: 10.1038/Mt.2015.197 |
0.746 |
|
| 2016 |
Perdoni C, Osborn MJ, Tolar J. Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa. Translational Research : the Journal of Laboratory and Clinical Medicine. 168: 50-8. PMID 26073463 DOI: 10.1016/J.Trsl.2015.05.008 |
0.432 |
|
| 2016 |
Thangavelu G, Saha A, Aoyama K, McDonald-Hyman C, Lee Y, Brown C, Panoskaltsis-Mortari A, Osborn MJ, Chandraratna RA, Noelle R, Blazar BR. Critical Roles of Retinoic Acid Signaling in Combating Acute Graft Versus Host Disease Blood. 128: 4534-4534. DOI: 10.1182/Blood.V128.22.4534.4534 |
0.522 |
|
| 2016 |
Knipping F, Petri K, Ruggiero E, Osborn M, Tolar J, Schmidt M, Kalle Cv, Gabriel R. 121. T Cell Receptor Modification by Highly Specific TALEN and CRISPR/Cas9 Molecular Therapy. 24. DOI: 10.1016/S1525-0016(16)32930-6 |
0.469 |
|
| 2016 |
Downs E, Osborn MJ, McGrath JA, Hovnanian A, Tamai K, Wagner J, Tolar J, Baldridge AD. Mo1263 Gastrointestinal Outcomes of Recessive Dystrophic Epidermolysis Bullosa After Hematopoietic Cell Transplantation Gastroenterology. 150. DOI: 10.1016/S0016-5085(16)32322-8 |
0.348 |
|
| 2016 |
Webber B, O’Connor K, McElmurry R, Durgin E, Riddle M, Osborn M, Tolar J. 419 Efficient CRISPR/Cas9-mediated knockout of Col7a1 in NOD/SCID IL2Rgamma-null mice by pro-nuclear injection Journal of Investigative Dermatology. 136: S74. DOI: 10.1016/J.Jid.2016.02.453 |
0.647 |
|
| 2016 |
Osborn M, Webber B, McElroy A, Defeo A, Patel D, Lees C, McElmurry R, Riddle M, Blazar B, Tolar J. 371 CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa (RDEB) Journal of Investigative Dermatology. 136: S66. DOI: 10.1016/J.Jid.2016.02.404 |
0.67 |
|
| 2016 |
Tolar J, McGrath J, Osborn MJ, Keene D, Hook K, Hordinsky MK, Marinkovich P, Woodley D, Chen M, Hovnanian A, Tamai K, Blazar B, Wagner J. 263 Skin engraftment and type VII collagen (C7) expression after allogeneic hematopoietic cell transplantation (HCT) for generalized severe recessive dystrophic epidermolysis bullosa (RDEB) Journal of Investigative Dermatology. 136. DOI: 10.1016/J.Jid.2016.02.293 |
0.384 |
|
| 2015 |
Veenstra RG, Flynn R, Kreymborg K, McDonald-Hyman C, Saha A, Taylor PA, Osborn MJ, Panoskaltsis-Mortari A, Schmitt-Graeff A, Lieberknect E, Murphy WJ, Serody JS, Munn DH, Freeman GJ, Allison JP, et al. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood. 125: 3335-46. PMID 25814530 DOI: 10.1182/Blood-2014-09-603357 |
0.742 |
|
| 2015 |
Osborn MJ, Gabriel R, Webber BR, DeFeo AP, McElroy AN, Jarjour J, Starker CG, Wagner JE, Joung JK, Voytas DF, von Kalle C, Schmidt M, Blazar BR, Tolar J. Fanconi anemia gene editing by the CRISPR/Cas9 system. Human Gene Therapy. 26: 114-26. PMID 25545896 DOI: 10.1089/Hum.2014.111 |
0.729 |
|
| 2015 |
McDonald-Hyman C, Thangavelu G, Muller J, Zhang G, Kumari S, Saha A, Koehn BH, Mitchell JS, Fife BT, Serody JS, Osborn MJ, Hippen KL, Kelekar A, Munn DH, Altman A, et al. Protein Kinase C-Theta Interacts with mTORC2 and Vimentin to Limit Regulatory T-Cell Function Blood. 126: 849-849. DOI: 10.1182/Blood.V126.23.849.849 |
0.523 |
|
| 2015 |
Tolar J, McGrath JA, Osborn MJ, Keene DR, Hook K, Hordinsky M, Woodley D, Chen M, Hovnanian A, Tamai K, Blazar BR, Wagner JE. Mucocutaneous Engraftment and Type VII Collagen (C7) Replacement after Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) Blood. 126: 402-402. DOI: 10.1182/Blood.V126.23.402.402 |
0.53 |
|
| 2015 |
Osborn MJ, Webber BR, Knipping F, Lonetree C, DeFeo A, McElroy A, Starker C, Gabriel R, Merkel S, Hippen KL, Voytas D, von Kalle C, Schmidt M, Miller JS, Jarjour J, et al. Megatal, Crispr/Cas9, and Talen T-Cell Receptor Gene Editing Blood. 126: 2045-2045. DOI: 10.1182/Blood.V126.23.2045.2045 |
0.763 |
|
| 2015 |
Knipping F, Petri K, Ruggiero E, Osborn MJ, Tolar J, Kalle Cv, Schmidt M, Gabriel R. 562. Modification of TCR Specificity by TALEN and CRISPR Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)34171-5 |
0.464 |
|
| 2014 |
Tolar J, McGrath JA, Xia L, Riddle MJ, Lees CJ, Eide C, Keene DR, Liu L, Osborn MJ, Lund TC, Blazar BR, Wagner JE. Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa. The Journal of Investigative Dermatology. 134: 1246-54. PMID 24317394 DOI: 10.1038/Jid.2013.523 |
0.578 |
|
| 2013 |
Dietz WM, Skinner NE, Hamilton SE, Jund MD, Heitfeld SM, Litterman AJ, Hwu P, Chen ZY, Salazar AM, Ohlfest JR, Blazar BR, Pennell CA, Osborn MJ. Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8+ T-cell responses. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1526-35. PMID 23689601 DOI: 10.1038/Mt.2013.85 |
0.488 |
|
| 2013 |
Osborn MJ, Starker CG, McElroy AN, Webber BR, Riddle MJ, Xia L, DeFeo AP, Gabriel R, Schmidt M, von Kalle C, Carlson DF, Maeder ML, Joung JK, Wagner JE, Voytas DF, et al. TALEN-based gene correction for epidermolysis bullosa. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1151-9. PMID 23546300 DOI: 10.1038/Mt.2013.56 |
0.753 |
|
| 2013 |
Tolar J, Xia L, Lees CJ, Riddle M, McElroy A, Keene DR, Lund TC, Osborn MJ, Marinkovich MP, Blazar BR, Wagner JE. Keratinocytes from induced pluripotent stem cells in junctional epidermolysis bullosa. The Journal of Investigative Dermatology. 133: 562-5. PMID 22931927 DOI: 10.1038/Jid.2012.278 |
0.553 |
|
| 2013 |
Tolar J, McGrath JA, Osborn MJ, Hook KP, Keene DR, Hordinsky MK, Blazar BR, Wagner JE. Bone Marrow Is the Preferred Graft for Allogeneic Hematopoietic Cell Transplantation (HCT) in Severe Epidermolysis Bullosa Biology of Blood and Marrow Transplantation. 19. DOI: 10.1016/J.Bbmt.2012.11.135 |
0.477 |
|
| 2012 |
Christian ML, Demorest ZL, Starker CG, Osborn MJ, Nyquist MD, Zhang Y, Carlson DF, Bradley P, Bogdanove AJ, Voytas DF. Targeting G with TAL effectors: a comparison of activities of TALENs constructed with NN and NK repeat variable di-residues. Plos One. 7: e45383. PMID 23028976 DOI: 10.1371/Journal.Pone.0045383 |
0.326 |
|
| 2012 |
Tolar J, McGrath JA, Osborn MJ, Hook KP, Keene DR, Hordinsky MK, Blazar BR, Wagner JE. Allogeneic Hematopoietic Cell Transplantation for Severe Epidermolysis Bullosa: Impact of Conditioning Regimen and Stem Cell Source On Outcomes Blood. 120: 965-965. DOI: 10.1182/Blood.V120.21.965.965 |
0.481 |
|
| 2011 |
Osborn MJ, DeFeo AP, Blazar BR, Tolar J. Synthetic zinc finger nuclease design and rapid assembly. Human Gene Therapy. 22: 1155-65. PMID 21663559 DOI: 10.1089/Hum.2011.072 |
0.499 |
|
| 2011 |
Tolar J, Xia L, Riddle MJ, Lees CJ, Eide CR, McElmurry RT, Titeux M, Osborn MJ, Lund TC, Hovnanian A, Wagner JE, Blazar BR. Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. The Journal of Investigative Dermatology. 131: 848-56. PMID 21124339 DOI: 10.1038/Jid.2010.346 |
0.58 |
|
| 2011 |
Osborn MJ, McElmurry RT, Lees CJ, DeFeo AP, Chen ZY, Kay MA, Naldini L, Freeman G, Tolar J, Blazar BR. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 450-60. PMID 21081900 DOI: 10.1038/Mt.2010.249 |
0.529 |
|
| 2011 |
Tolar J, Park IH, Xia L, Lees CJ, Peacock B, Webber B, McElmurry RT, Eide CR, Orchard PJ, Kyba M, Osborn MJ, Lund TC, Wagner JE, Daley GQ, Blazar BR. Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). Blood. 117: 839-47. PMID 21037085 DOI: 10.1182/Blood-2010-05-287607 |
0.75 |
|
| 2010 |
Wagner JE, Ishida-Yamamoto A, McGrath JA, Hordinsky M, Keene DR, Woodley DT, Chen M, Riddle MJ, Osborn MJ, Lund T, Dolan M, Blazar BR, Tolar J. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. The New England Journal of Medicine. 363: 629-39. PMID 20818854 DOI: 10.1056/Nejmoa0910501 |
0.538 |
|
| 2010 |
Kelly RM, Goren EM, Taylor PA, Mueller SN, Stefanski HE, Osborn MJ, Scott HS, Komarova EA, Gudkov AV, Holländer GA, Blazar BR. Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation. Blood. 115: 1088-97. PMID 19965631 DOI: 10.1182/Blood-2009-05-223198 |
0.542 |
|
| 2009 |
Tolar J, Ishida-Yamamoto A, Riddle M, McElmurry RT, Osborn M, Xia L, Lund T, Slattery C, Uitto J, Christiano AM, Wagner JE, Blazar BR. Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood. 113: 1167-74. PMID 18955559 DOI: 10.1182/Blood-2008-06-161299 |
0.495 |
|
| 2009 |
Wagner JE, Ishida-Yamamoto A, McGrath JA, Hordinsky M, Keene DR, Osborn M, Lund T, Dolan M, Blazar BR, Tolar J. First Use of Allogeneic Stem Cells in the Treatment of Recessive Dystrophic Epidermolysis Bullosa: Demonstration of Biochemical and Clinical Improvement. Blood. 114: 660-660. DOI: 10.1182/Blood.V114.22.660.660 |
0.537 |
|
| 2008 |
Osborn MJ, McElmurry RT, Peacock B, Tolar J, Blazar BR. Targeting of the CNS in MPS-IH Using a Nonviral Transferrin-α-l-iduronidase Fusion Gene Product. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1459-1466. PMID 28182871 DOI: 10.1038/Mt.2008.119 |
0.476 |
|
| 2008 |
Osborn MJ, McElmurry RT, Peacock B, Tolar J, Blazar BR. Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1459-66. PMID 18523448 DOI: 10.1038/mt.2008.119 |
0.395 |
|
| 2008 |
Tolar J, Park I, Xia L, Osborn M, McElmurry RT, Orchard PJ, Daley GQ, Blazar BR. Patient-Specific Induced Pluripotent Stem Cells in Hurler Syndrome Blood. 112: 386-386. DOI: 10.1182/Blood.V112.11.386.386 |
0.604 |
|
| 2007 |
Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, Xia L, Zhou N, Riddle M, Schroeder TM, Westendorf JJ, McIvor RS, Hogendoorn PC, Szuhai K, Oseth L, et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (Dayton, Ohio). 25: 371-9. PMID 17038675 DOI: 10.1634/Stemcells.2005-0620 |
0.51 |
|
| 2006 |
Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis-Mortari A, McElmurry RT, Bell S, Xia L, Zhou N, Riddle M, Schroeder TM, Westendorf JJ, McIvor RS, Hogendoom PC, Szuhai K, Oseth L, et al. Osteosarcoma Derived from Cultured Mesenchymal Stem Cells. Blood. 108: 2554-2554. DOI: 10.1182/Blood.V108.11.2554.2554 |
0.515 |
|
| 2005 |
Osborn MJ, Panoskaltsis-Mortari A, McElmurry RT, Bell SK, Vignali DA, Ryan MD, Wilber AC, McIvor RS, Tolar J, Blazar BR. A picornaviral 2A-like sequence-based tricistronic vector allowing for high-level therapeutic gene expression coupled to a dual-reporter system. Molecular Therapy : the Journal of the American Society of Gene Therapy. 12: 569-74. PMID 15964244 DOI: 10.1016/J.Ymthe.2005.04.013 |
0.466 |
|
| 2005 |
Tolar J, Osborn M, Bell S, McElmurry R, Xia L, Riddle M, Panoskaltsis-Mortari A, Jiang Y, McIvor RS, Contag CH, Yant SR, Kay MA, Verfaillie CM, Blazar BR. Real-time in vivo imaging of stem cells following transgenesis by transposition. Molecular Therapy : the Journal of the American Society of Gene Therapy. 12: 42-8. PMID 15963919 DOI: 10.1016/J.Ymthe.2005.02.023 |
0.516 |
|
| 2005 |
Tolar J, Osborn MJ, Panoskaltsis-Mortari A, McElmurry RT, Bell S, Xia L, Riddle M, Schroeder TM, Westendorf JJ, McIvor RS, Oseth L, Hirsch B, Yant SR, Kay MA, Peister A, et al. Mesenchymal Cancer Cells Can Arise from Ex Vivo Modified Mesenchymal Stem Cells. Blood. 106: 4326-4326. DOI: 10.1182/Blood.V106.11.4326.4326 |
0.543 |
|
| 2004 |
Osborn MJ, Ryan PL, Kirchhof N, Panoskaltsis-Mortari A, Mortari F, Tudor KS. Overexpression of murine TSLP impairs lymphopoiesis and myelopoiesis. Blood. 103: 843-51. PMID 14512322 DOI: 10.1182/Blood-2003-05-1557 |
0.376 |
|
| 2004 |
Tolar J, Osborn M, Bell S, Xia L, Riddle M, Panoskaltsis-Mortari A, McIvor S, Stephen YR, Kay MA, Contag CH, Verfaillie CM, Blazar BR. Transgenesis of Multipotent Adult Progenitor Cells (MAPC) with Sleeping Beauty Transposons to Determine MAPC Homing and Persistence in Real-Time In Vivo. Blood. 104: 2099-2099. DOI: 10.1182/Blood.V104.11.2099.2099 |
0.576 |
|
| Show low-probability matches. |